Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15775392 | 0.98 | UGT2B7 (0.46) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL9005796 | 0.80 | UGT2B7 (0.47) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL10402565 | 0.80 | UGT2B7 (0.47) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL11323036 | 0.79 | UGT2B7 (0.50) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| Hydrochloric Acid SCHEMBL10821283 | 0.78 | UGT2B7 (0.46) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL12569123 | 0.76 | UGT2B7 (0.56) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL10359867 | 0.76 | UGT2B7 (0.56) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL3038889 | 0.76 | UGT2B7 (0.56) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL15614046 | 0.76 | UGT2B7 (0.56) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL12568798 | 0.76 | UGT2B7 (0.56) | UGT2B7SLC6A2SLC6A4SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | claimed |
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | claimed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| EP-2657214-B1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-02-15 | — | — | EP | disclosed |
| WO-2016044777-A1 | HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044777-A1 | HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-22 | — | — | US | disclosed |
| EP-2925746-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8993774-B2 | Process for production of aromatic alcohol or heterocyclic aromatic alcohol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| WO-2014086663-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-11-14 | — | — | US | disclosed |
| EP-2657214-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| CN-1111162-C | Artemisinin derivatives, method for preparation thereof and pharmaceutical compositions containing the same | SHANGHAI INST OF MATERIAL MEDI (CN) | 2003-06-11 | — | — | CN | disclosed |
| US-6307068-B1 | TREATING OR IN PREVENTING CANCER. | ADIR ET COMPAGNIE (FR) | 2001-10-23 | — | — | US | disclosed |
| CN-1305482-A | Artemisinin derivatives, method for preparation thereof and pharmaceutical compositions containing the same | SHANGHAI INST OF MATERIAL MEDI (CN) | 2001-07-25 | — | — | CN | disclosed |
| EP-1086107-A1 | ARTEMISININ DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065914-A1 | ARTEMISININ DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SHANGHAI INSTITUTE OF MATERIA MEDICA (CN) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299143-A1 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS | HDAC7, PSMB7, IKZF3 | UGT2B7 37/4885SLC6A2 4413/4885SLC6A4 3758/4885 |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | ADH1C, ADH1A, ADH5 | UGT2B7 682/4885SLC6A2 1320/4885SLC6A4 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.